Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

June 3, 2020June 3, 2020

Mortality Risk 37% Lower in IPF Patients on Ofev or Esbriet, Study Reports

Esbriet, News

Idiopathic pulmonary fibrosis (IPF) patients taking antifibrotic therapies Ofev (nintedanib) or Esbriet (pirfenidone) had a mortality risk that was 37% lower than patients not treated with such therapies, a large registry-based study ... Read more

May 27, 2020May 27, 2020

Real-world Study Supports Effectiveness, Safety of Esbriet for Treating IPF

Esbriet, News

A real-world, multi-center study in Poland confirms the effectiveness and safety of two-year treatment with Esbriet (pirfenidone) for people with idiopathic pulmonary fibrosis (IPF). The study “A multicentre retrospective observational study on ... Read more

May 15, 2020May 15, 2020

Lung CT Scans May Help Predict Mortality Risk of IPF Patients

News

Lung evaluations via a CT scan might help predict the mortality risk in idiopathic pulmonary fibrosis (IPF) patients more accurately than the decline in forced vital capacity, a study ... Read more

May 12, 2020July 1, 2020

Phase 2 Trial of Inhaled IPF Therapy Enrolling as Planned, Galecto Says

Covid-19, News

The Phase 2b GALACTIC-1 trial testing Galecto’s candidate GB0139 as an inhalation therapy for idiopathic pulmonary fibrosis (IPF) has recruited more than 150 patients to date, remaining on track despite ... Read more

April 29, 2020April 30, 2020

Cell Therapy Reduces Fibrosis in PF Rat Models, Prompting Launch of Future Human Trial

News

A cell therapy based on human and rat lung progenitor cells — called lung spheroid cells — reduced scarring (fibrosis) when infused in two rat models of pulmonary fibrosis ... Read more

April 7, 2020July 1, 2020

Home Oxygen Therapy No Longer Requires In-Person Testing and Signature Due to COVID-19 Risk

Covid-19, News

The Centers for Medicare and Medicaid Services (CMS) has waived all requirements for in-person testing and signature at delivery for supplemental oxygen during the COVID-19 pandemic. The Pulmonary Fibrosis ... Read more

March 18, 2020March 18, 2020

UK Trial Recruiting IPF Patients to Test Nalbuphine Extended Release Tablets for Chronic Cough

News

A clinical trial in the U.K. is recruiting people with idiopathic pulmonary fibrosis (IPF) to test Trevi Therapeutics’ nalbuphine extended release tablets to treat chronic cough, the company announced. ... Read more

March 13, 2020March 13, 2020

Bellerophon, FDA Agree on Design of Phase 3 INOpulse Trial

News

The U.S. Food and Drug Administration (FDA) and Bellerophon Therapeutics agreed on the design of Bellerophon’s Phase 3 trial to test INOpulse — inhaled nitric oxide — in people with pulmonary fibrosis ... Read more

March 12, 2020March 12, 2020

Pediatric Rare Disease Therapies Increase, But Most Repurposed, Study Finds

News

The number of treatments for children with rare diseases has grown over the past decade, according to a new study. However, despite the increase, nearly 7,000 rare diseases are still ... Read more

March 10, 2020March 10, 2020

Target FPR-1 Protein or Neutrophils in Fibrotic Lungs, Mouse Study Suggests

News

The FPR-1 protein is necessary for the recruitment of immune cells, namely neutrophils and inflammatory macrophages, to the lungs where they promote pulmonary fibrosis (PF), a mouse study shows. ... Read more

Pin It on Pinterest